LMO2 and leukemia: This was demonstrated in early retroviral HSC IL2RG gene therapy for X-SCID patients, in which 4 of the 10 treated patients eventually developed leukemia, likely due to LMO2 activation induced by integration of the retrovirus and cooperation between the functions of LMO2 and IL2RG67.